Patents by Inventor Jianliang Shi

Jianliang Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220119388
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 18, 2021
    Publication date: April 21, 2022
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael C. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • Publication number: 20210121453
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: September 4, 2020
    Publication date: April 29, 2021
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Patent number: 10913738
    Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: February 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Publication number: 20200347071
    Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
    Type: Application
    Filed: January 24, 2019
    Publication date: November 5, 2020
    Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
  • Publication number: 20200277296
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 29, 2018
    Publication date: September 3, 2020
    Inventors: Michael E. Mertzman, Carolyn Diane Dzierba, Jason M. Guernon, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Steven H. Spergel
  • Publication number: 20200163949
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Publication number: 20190389859
    Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Application
    Filed: February 12, 2018
    Publication date: December 26, 2019
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Publication number: 20190314358
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Publication number: 20190117638
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 25, 2019
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Publication number: 20180250283
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 6, 2018
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Publication number: 20180110766
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: December 19, 2017
    Publication date: April 26, 2018
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Publication number: 20180000807
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: September 15, 2017
    Publication date: January 4, 2018
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Publication number: 20170258777
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 14, 2017
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Publication number: 20160081995
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: October 13, 2015
    Publication date: March 24, 2016
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Patent number: 9221796
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: December 29, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Publication number: 20150336975
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Application
    Filed: August 3, 2015
    Publication date: November 26, 2015
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • Publication number: 20150191452
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: January 5, 2015
    Publication date: July 9, 2015
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • Publication number: 20150152089
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 4, 2015
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • Patent number: 8710061
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: April 29, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • Patent number: 8637525
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: January 28, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev